Updates are available Correction dated 2025-11-19
Click to view Correction: https://doi.org/10.1038/s43587-025-01037-3
-
Authors
Sproviero, Daisy https://orcid.org/0000-0001-5061-683X
Payán-Gómez, César
Milanese, Chiara https://orcid.org/0000-0001-8696-2603
Barnhoorn, Sander
Sun, Shixiang https://orcid.org/0000-0001-5499-2963
Gyenis, Akos
Delia, Domenico
Lashley, Tammaryn https://orcid.org/0000-0001-7389-0348
Hoeijmakers, Jan H. J. https://orcid.org/0000-0003-3526-7795
Vijg, Jan https://orcid.org/0000-0002-8457-9595
Mastroberardino, Pier G. https://orcid.org/0000-0003-2364-4258
-
Funding
Funding for this research was provided by:
Michael J. Fox Foundation for Parkinson's Research (MJFF-021185)
Michael J. Fox Foundation for Parkinson's Research (MJFF-021185)
Fondazione Umberto Veronesi
- License Information
-
More Information
Article History
Received: 18 August 2023
Accepted: 24 June 2025
First Online: 5 September 2025
Change Date: 19 November 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s43587-025-01037-3
Competing interests
: P.G.M. is an inventor on a patent application related to the use of a DNA damage molecular signature in the blood for prognostic purposes in Parkinson’s disease. J.V. is a founder and shareholder of MutaGentech, Inc. D.S., C.P.-G., C.M., S.B., S.S., A.G., D.D., T.L. and J.H.J.H. declare no competing interests.
